Compare ORA & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORA | CRL |
|---|---|---|
| Founded | 1965 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.0B |
| IPO Year | 2004 | 2000 |
| Metric | ORA | CRL |
|---|---|---|
| Price | $125.85 | $220.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $121.44 | ★ $205.27 |
| AVG Volume (30 Days) | 558.5K | ★ 664.0K |
| Earning Date | 02-25-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | $944,248,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $17.90 | $1.70 |
| P/E Ratio | $57.92 | ★ N/A |
| Revenue Growth | ★ 6.07 | N/A |
| 52 Week Low | $61.58 | $91.86 |
| 52 Week High | $126.36 | $228.88 |
| Indicator | ORA | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 59.95 |
| Support Level | $115.35 | $217.57 |
| Resistance Level | $125.35 | $228.39 |
| Average True Range (ATR) | 3.16 | 7.21 |
| MACD | 0.71 | -0.79 |
| Stochastic Oscillator | 95.21 | 56.56 |
Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.